You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Ranitidine hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for ranitidine hydrochloride and what is the scope of freedom to operate?

Ranitidine hydrochloride is the generic ingredient in seven branded drugs marketed by Ajanta Pharma Ltd, Appco, Aurobindo Pharma, Dr Reddys Labs Ltd, Norvium Bioscience, Novitium Pharma, Sandoz, Teva, Glaxosmithkline, Glaxo Grp Ltd, Bedford, Hikma, Mylan Labs Ltd, Zydus Pharms Usa Inc, Pai Holdings Pharm, Actavis Mid Atlantic, Amneal Pharms, Apotex Inc, Epic Pharma Llc, Lannett Co Inc, Nostrum Labs Inc, Pharm Assoc, Ranbaxy, Taro, Tolmar, Torrent, Wockhardt, Chattem Sanofi, Amneal Pharms Ny, Ani Pharms, Apotex, Boehringer Ingelheim, Contract Pharmacal, Dr Reddys Labs Inc, Endo Operations, Glenmark Pharms Inc, Granules, Heritage Pharma Avet, Mylan, Perrigo, Perrigo R And D, Strides Pharma, Sun Pharm Inds Ltd, Thinq Pharm-cro Pvt, Vkt Pharma, Watson Labs, and Wockhardt Ltd, and is included in eighty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for ranitidine hydrochloride. Twelve suppliers are listed for this compound.

Summary for ranitidine hydrochloride
US Patents:0
Tradenames:7
Applicants:47
NDAs:84
Drug Master File Entries: 32
Finished Product Suppliers / Packagers: 12
Raw Ingredient (Bulk) Api Vendors: 169
Clinical Trials: 140
Patent Applications: 2,839
What excipients (inactive ingredients) are in ranitidine hydrochloride?ranitidine hydrochloride excipients list
DailyMed Link:ranitidine hydrochloride at DailyMed
Recent Clinical Trials for ranitidine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kasr El Aini HospitalN/A
Menoufia UniversityPhase 2/Phase 3
Cairo UniversityN/A

See all ranitidine hydrochloride clinical trials

Pharmacology for ranitidine hydrochloride

US Patents and Regulatory Information for ranitidine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Thinq Pharm-cro Pvt RANITIDINE HYDROCHLORIDE ranitidine hydrochloride TABLET;ORAL 210250-001 Aug 30, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi ZANTAC 150 ranitidine hydrochloride TABLET;ORAL 021698-002 Mar 13, 2007 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Wockhardt RANITIDINE HYDROCHLORIDE ranitidine hydrochloride TABLET;ORAL 078653-001 Nov 26, 2007 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Endo Operations RANITIDINE HYDROCHLORIDE ranitidine hydrochloride TABLET;ORAL 075180-002 Jan 28, 1999 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lannett Co Inc RANITIDINE HYDROCHLORIDE ranitidine hydrochloride SYRUP;ORAL 078890-001 Jul 1, 2010 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Apotex RANITIDINE HYDROCHLORIDE ranitidine hydrochloride TABLET;ORAL 074680-001 Sep 12, 1997 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ranitidine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pai Holdings Pharm ZANTAC IN PLASTIC CONTAINER ranitidine hydrochloride INJECTABLE;INJECTION 019593-002 Sep 27, 1991 ⤷  Sign Up ⤷  Sign Up
Pai Holdings Pharm ZANTAC IN PLASTIC CONTAINER ranitidine hydrochloride INJECTABLE;INJECTION 019593-002 Sep 27, 1991 ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 ⤷  Sign Up ⤷  Sign Up
Pai Holdings Pharm ZANTAC ranitidine hydrochloride INJECTABLE;INJECTION 019090-001 Oct 19, 1984 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline ZANTAC 150 ranitidine hydrochloride CAPSULE;ORAL 020095-001 Mar 8, 1994 ⤷  Sign Up ⤷  Sign Up
Glaxo Grp Ltd ZANTAC 150 ranitidine hydrochloride TABLET, EFFERVESCENT;ORAL 020251-001 Mar 31, 1994 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.